AstraZeneca's Nasal Flu Vaccine Targets Needle-Phobic Children for Better Protection
More children died from flu this past season than any year outside the 2009 swine flu pandemic, mostly unvaccinated. Doctors hope AstraZeneca's FluMist Home nasal vaccine, approved for ages 2 and up and adults under 50, improves vaccination rates among needle-phobic children. A 2019 study shows most children and up to 30% of young adults fear needles. Dr. Zachary Hoy notes children often don't understand vaccines' importance. FluMist, reformulated after 2016 CDC restrictions, matches circulating strains and is as effective as injectable vaccines. It's available online with insurance billing and a temperature monitor for safety. Uninsured or insurance-excluded patients have out-of-pocket options. Experts caution improper use without supervision, but emphasize vaccines work only when administered.